- Home
- PROK vs RDZN Comparison
PROK vs RDZN Comparison
Compare PROK & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- RDZN
- Stock Information
- Founded
- PROK 2015
- RDZN 2015
- Country
- PROK United States
- RDZN United States
- Employees
- PROK N/A
- RDZN N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- RDZN Blank Checks
- Sector
- PROK Health Care
- RDZN Finance
- Exchange
- PROK Nasdaq
- RDZN Nasdaq
- Market Cap
- PROK 94.9M
- RDZN 79.4M
- IPO Year
- PROK N/A
- RDZN N/A
- Fundamental
- Price
- PROK $0.98
- RDZN $1.02
- Analyst Decision
- PROK Buy
- RDZN Strong Buy
- Analyst Count
- PROK 4
- RDZN 2
- Target Price
- PROK $5.00
- RDZN $5.00
- AVG Volume (30 Days)
- PROK 522.0K
- RDZN 344.8K
- Earning Date
- PROK 05-12-2025
- RDZN 07-01-2025
- Dividend Yield
- PROK N/A
- RDZN N/A
- EPS Growth
- PROK N/A
- RDZN N/A
- EPS
- PROK N/A
- RDZN N/A
- Revenue
- PROK $306,000.00
- RDZN $42,893,256.00
- Revenue This Year
- PROK $54.34
- RDZN $4.52
- Revenue Next Year
- PROK N/A
- RDZN $53.72
- P/E Ratio
- PROK N/A
- RDZN N/A
- Revenue Growth
- PROK N/A
- RDZN 2.79
- 52 Week Low
- PROK $0.46
- RDZN $0.68
- 52 Week High
- PROK $3.43
- RDZN $3.28
- Technical
- Relative Strength Index (RSI)
- PROK 65.88
- RDZN 51.37
- Support Level
- PROK $0.75
- RDZN $0.96
- Resistance Level
- PROK $0.82
- RDZN $1.13
- Average True Range (ATR)
- PROK 0.07
- RDZN 0.15
- MACD
- PROK 0.03
- RDZN 0.01
- Stochastic Oscillator
- PROK 88.17
- RDZN 38.78
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.